Better Access to Healthcare for Indigenous Peoples
Indigenous Peoples often experience poor access to health care. Our initiatives from Canada and New Zealand aim to overcome the gap.
Search
Nerandomilast primary endpoint phase-3 FIBRONEER-IPF met
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Growing with us
We recognize the benefits of learning and have created an environment where life-long learning and personal growth are encouraged for all employees.
Phase II clinical trial weight loss results
Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
Spesolimab Phase II data
New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
Spesolimab meets key endpoint for GPP flare prevention
Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
emperor-preserved-chmp-positive-opinion
CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction
real-world-benefit-shown-in-T2D-treatment
Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
reduced-heart-failure-treatment-approval-europe
European approval for treatment of adults with heart failure with reduced ejection fraction
FDA- HFpEF-breakthrough-designation-EMPEROR-preserved
U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction
preserved-heart-failure-treatment-FDA-US-approval
US FDA approves Jardiance® (empagliflozin) to treat adults with heart failure regardless of left ventricular ejection fraction
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
emperor-preserved-heart-failure-toplineresults
Positive, top-line results announced from the EMPEROR-Preserved Phase III trial in adults with heart failure with preserved ejection fraction
emperor-reduced-chmp-positive-opinion
CHMP issues positive opinion for the treatment of adults with heart failure with reduced ejection fraction
emperor-preserved-kidney-subanalysis
New kidney sub-analysis of EMPEROR-Preserved trial demonstrates significant improvement in heart failure outcomes regardless of kidney disease status
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
Geographic Atrophy treatment to move to Phase II
Geographic Atrophy treatment BI 771716 to move to Phase II, following positive Phase I results
emperor-preserved-heart-failure-full-data
Full results from EMPEROR-Preserved trial demonstrate significant improvement in heart failure outcomes in adults with preserved ejection fraction
survodutide top-line results MASH fibrosis
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
Breakthrough Phase 2 survodutide data liver fibrosis MASH
Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis